These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 28042702)

  • 41. Two cases of late onset familial amyloid polyneuropathy with a Glu61Lys transthyretin variant.
    Nakano Y; Tadokoro K; Ohta Y; Sato K; Takemoto M; Hishikawa N; Yamashita T; Yamashita T; Ando Y; Abe K
    J Neurol Sci; 2018 Jul; 390():22-25. PubMed ID: 29801893
    [No Abstract]   [Full Text] [Related]  

  • 42. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial.
    Waddington-Cruz M; Ackermann EJ; Polydefkis M; Heitner SB; Dyck PJ; Barroso FA; Wang AK; Berk JL; Dyck PJB; Monia BP; Hughes SG; Tai L; Jesse Kwoh T; Jung SW; Coelho T; Benson MD; Gertz MA
    Amyloid; 2018 Sep; 25(3):180-188. PubMed ID: 30169969
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Curcumin could reduce the monomer of TTR with Tyr114Cys mutation via autophagy in cell model of familial amyloid polyneuropathy.
    Li H; Zhang Y; Cao L; Xiong R; Zhang B; Wu L; Zhao Z; Chen SD
    Drug Des Devel Ther; 2014; 8():2121-8. PubMed ID: 25382970
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy.
    Benson MD; Dasgupta NR; Rissing SM; Smith J; Feigenbaum H
    Amyloid; 2017 Dec; 24(4):219-225. PubMed ID: 28906150
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [What gnaws at the heart and gets on the nerves].
    Kristen AV
    Internist (Berl); 2018 Nov; 59(11):1208-1213. PubMed ID: 30039176
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cardiac involvement, morbidity and mortality in hereditary transthyretin amyloidosis because of p.Glu89Gln mutation.
    Gospodinova M; Sarafov S; Chamova T; Kirov A; Todorov T; Nakov R; Todorova A; Denchev S; Tournev I
    J Cardiovasc Med (Hagerstown); 2020 Sep; 21(9):688-695. PubMed ID: 32740500
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reduced myocardial 123-iodine metaiodobenzylguanidine uptake: a prognostic marker in familial amyloid polyneuropathy.
    Coutinho MC; Cortez-Dias N; Cantinho G; Conceição I; Oliveira A; Bordalo e Sá A; Gonçalves S; Almeida AG; de Carvalho M; Diogo AN
    Circ Cardiovasc Imaging; 2013 Sep; 6(5):627-36. PubMed ID: 23833285
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Familial amyloidotic polyneuropathy and transthyretin.
    Nagasaka T
    Subcell Biochem; 2012; 65():565-607. PubMed ID: 23225017
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Systemic angiopathy and axonopathy in hereditary transthyretin amyloidosis with Ala97Gly (p. Ala117Gly) mutation: a post-mortem analysis.
    Koike H; Yasuda T; Nishi R; Ikeda S; Kawagashira Y; Iijima M; Sobue G; Katsuno M
    Amyloid; 2018 Jun; 25(2):141-142. PubMed ID: 29855203
    [No Abstract]   [Full Text] [Related]  

  • 50. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis.
    Quarta CC; Solomon SD; Uraizee I; Kruger J; Longhi S; Ferlito M; Gagliardi C; Milandri A; Rapezzi C; Falk RH
    Circulation; 2014 May; 129(18):1840-9. PubMed ID: 24563469
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predictors of survival stratification in patients with wild-type cardiac amyloidosis.
    Siepen FAD; Bauer R; Voss A; Hein S; Aurich M; Riffel J; Mereles D; Röcken C; Buss SJ; Katus HA; Kristen AV
    Clin Res Cardiol; 2018 Feb; 107(2):158-169. PubMed ID: 28956153
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tafamidis for transthyretin amyloid cardiomyopathy: the solution or just the beginning of the end?
    Falk RH
    Eur Heart J; 2019 Mar; 40(12):1009-1012. PubMed ID: 30668704
    [No Abstract]   [Full Text] [Related]  

  • 53. Diflunisal compassive use in transthyretin hereditary amyloid polyneuropathy: report of a first Spanish experience.
    Azorín SE; Cabib CE; Campistol JM
    Amyloid; 2017 Mar; 24(sup1):105-106. PubMed ID: 28434315
    [No Abstract]   [Full Text] [Related]  

  • 54. The current status of the Transthyretin Amyloidosis Outcomes Survey (THAOS) in Japan.
    Sekijima Y; Mundayat R; Ishii T; Ando Y
    Amyloid; 2019; 26(sup1):61-62. PubMed ID: 31343365
    [No Abstract]   [Full Text] [Related]  

  • 55. Acoramidis in Transthyretin Amyloid Cardiomyopathy.
    Verbeeck J; De Backer M; Buyse M
    N Engl J Med; 2024 Apr; 390(14):1345-1346. PubMed ID: 38598811
    [No Abstract]   [Full Text] [Related]  

  • 56. Acoramidis in Transthyretin Amyloid Cardiomyopathy.
    Groothof D; Nienhuis HLA; Bakker SJL
    N Engl J Med; 2024 Apr; 390(14):1346. PubMed ID: 38598812
    [No Abstract]   [Full Text] [Related]  

  • 57. Primary Cardiac Involvement in the Rare Transthyretin Ile73Val Mutation: A Case Series.
    Kumar P; Paramasivam G; Devasia T; K P; A M; Nayak K; Joshi MB; Moka R
    Circ Genom Precis Med; 2020 Jun; 13(3):e002792. PubMed ID: 32393063
    [No Abstract]   [Full Text] [Related]  

  • 58. Hereditary amyloidosis with cardiomyopathy caused by the novel variant transthyretin A36D.
    Yamashita T; Ueda M; Saga N; Nanto K; Tasaki M; Masuda T; Misumi Y; Oda S; Fujimoto A; Amano T; Takamatsu K; Yamashita S; Obayashi K; Matsui H; Ando Y
    Amyloid; 2016 Sep; 23(3):207-208. PubMed ID: 27646980
    [No Abstract]   [Full Text] [Related]  

  • 59. Mutant Thr95Ile Transthyretin-Related Cardiac Amyloidosis With Polyneuropathy.
    Kim K; Oh J; Lee ST; Shim HS; Kang SM
    Circ J; 2019 Oct; 83(11):2328. PubMed ID: 31243187
    [No Abstract]   [Full Text] [Related]  

  • 60. Letter by Rozenbaum et al Regarding Article, "Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy".
    Rozenbaum MH; Kemner J; Parasuraman B
    Circulation; 2020 Oct; 142(15):e210-e211. PubMed ID: 33044864
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.